An Open‐Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First‐Line HER2‐Positive Metastatic Breast Cancer

Abstract:

Background. Recent data support the hypothesis that combining lapatinib and trastuzumab with taxane chemotherapy may offer added clinical benefit to patients with human epidermal growth factor receptor 2 (HER2)‐positive metastatic breast cancer (MBC). This study examined the safety of the triplet combination in first‐line HER2‐positive MBC. Patients and Methods. Patients were enrolled into three sequential cohorts; the last two cohorts were added by protocol amendment following review of safety data from cohort 1. Patients in cohort 1 received lapatinib (1000 mg/day) plus paclitaxel (80 mg/m2 per week, 3 of every 4 weeks); cohort 2 received lapatinib (1000 mg/day) plus paclitaxel (70 mg/m2 per week, 3 of every 4 weeks); and cohort 3 received lapatinib (750 mg/day) plus paclitaxel (80 mg/m2 per week, 3 of every 4 weeks). All received standard trastuzumab dosing. The …

Año de publicación:

2013

Keywords:

Fuente:

google